SUPRENZA
PHENTERMINE HYDROCHLORIDE
Approval overview SUPRENZA is listed in Drugs@FDA under application 202088 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient PHENTERMINE HYDROCHLORIDE Form and strength TABLET, ORALLY DISINTEGRATING;ORAL - 37.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor CITIUS PHARMS Submission history Latest submission status date: 2014-02-18 00:00:00.
Structured Monograph
Clinical summary
Approval overview SUPRENZA is listed in Drugs@FDA under application 202088 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient PHENTERMINE HYDROCHLORIDE Form and strength TABLET, ORALLY DISINTEGRATING;ORAL - 37.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor CITIUS PHARMS Submission history Latest submission status date: 2014-02-18 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.